TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05178732

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose of protein
Description: One of three protein doses provided

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose of protein
Description: One of three protein doses provided

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose of protein
Description: One of three protein doses provided

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose of protein
Description: One of three protein doses provided

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose of protein
Description: One of three protein doses provided

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose of protein
Description: One of three protein doses provided

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menstrual cycle phase
Description: Different phase of the menstrual cycle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menstrual cycle phase
Description: Different phase of the menstrual cycle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menstrual cycle phase
Description: Different phase of the menstrual cycle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menstrual cycle phase
Description: Different phase of the menstrual cycle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menstrual cycle phase
Description: Different phase of the menstrual cycle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menstrual cycle phase
Description: Different phase of the menstrual cycle
Study: NCT05872776

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromodulation with RR2 device
Description: non-invasive neuromodulation with RR2 device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mock sham neuromodulation with sham RR2 device
Description: Mock sham stimulation with RR2 device
Study: NCT04746768

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: exercise and nutritional support
Description: exercise and nutritional support program during an active support phase (0 to 6 months) followed by an empowerment phase (from 6 to 12 months)
Study: NCT04747171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal Magnesium
Description: intrathecal adjuvants to bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal dexamthasone
Description: intrathecal adjuvants to bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal dexmedetomidine
Description: intrathecal adjuvants to bupivacaine
Study: NCT06463067

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: playing mobile game
Description: Changes in anxiety levels were measured by playing a mobile game to children before dental examination.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: reading book
Description: Changes in anxiety levels were measured by reading books to children before dental examination.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: watching video
Description: Changes in anxiety levels were measured by showing a video to children before dental examination.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: tell-show-do group
Description: Before the dental examination, the tell-show-do technique was applied to the children and the changes in their anxiety levels were measured.
Study: NCT05462210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization Protocol Assisted with Simulated Clinical Immersion Videos
Description: Mobilization Protocol Assisted with Simulated Clinical Immersion Videos Simulated clinical immersion videos created for the mobilization protocol for patients in the intervention group will be sent to their smartphones once they are admitted to the clinic. The videos prepared within the scope of the mobilization protocol will be watched by patients in company with the researcher the day before the operation, their questions will be answered, and the correct mobilization techniques will be shown practically. It is expected that patients watch the videos at least four times, as twice with the researcher and twice by themselves.
Study: NCT05048875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802 (sentinel high dose)
Description: Group 1a, JNJ-64281802 (high dose: 600-mg loading dose for 5 days/200-mg maintenance dose for 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802 (remaining high dose)
Description: Group 1b, JNJ-64281802 (high dose: 600-mg loading dose for 5 days/200-mg maintenance dose for 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802 (medium/low dose)
Description: Group 2, JNJ-64281802 (low dose: 40-mg loading dose for 5 days/10-mg maintenance dose for 21 days) AND JNJ-64281802 (medium dose: 200-mg loading dose for 5 days/50-mg maintenance dose for 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802 (daily dosing regimen X)
Description: Group 3, JNJ-64281802 (800-mg twice per day loading dose for 2 days/250-mg maintenance dose for 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802 (weekly dosing regimen Y1)
Description: Group 4, JNJ-64281802 (450-mg twice per day loading dose for 2 days/1200-mg maintenance dose weekly \[3 doses over 15 days\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802 (weekly dosing regimen Z2)
Description: Group 5, JNJ-64281802 (250-mg twice per day loading dose for 2 days/500-mg maintenance dose weekly \[3 doses over 15 days\])

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No therapeutic effect, used as a control in testing new drugs
Study: NCT04971005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Autologous Hematopoietic Stem Cell Transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab
Description: 600 mg every 6 months continuously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: 12 mg/day for 5 consecutive days and again after 365 days for 3 days
Study: NCT05210179

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TURKOVAC-Dollvet
Description: TURKOVAC-Dollvet vaccines produced by Dollvet Veterinary Vaccine Pharmaceutical Biological Substance Production Industry Co., Ltd.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TURKOVAC-Koçak
Description: TURKOVAC-Koçak vaccines produced by Koçak Farma Pharmaceutical and Chemical Industry Co., Ltd.
Study: NCT05429294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Patients with HER2-positive advanced/metastatic breast cancer are treated with pyrotinib combined with trastuzumab and albumin paclitaxel in the first-line setting.
Study: NCT05399459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant 25 MG
Description: Single dose of 25 mg orally disintegrating tablet of rimegepant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 MG
Description: Single dose of 75 mg orally disintegrating tablet of rimegepant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet
Study: NCT05248438

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire
Study: NCT06229951

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen
Description: Patients who have taken 480 mg of hydrolyzed collagen and 20 mg of undenatured type II collagen (in one tablet) 2 tabs a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control patients will take placebo 2 tabs a day.
Study: NCT05582642

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inspiratory Muscle Training (IMT)
Description: The training itself includes 2 x 30 breathing cycles per day. The whole training should take place daily, 7 days a week. The initial training intensity in the treatment arm (resistance of the respiratory muscle training) is set to 50% of the maximum respiratory muscle strength (measured using PImax). Once a week the present investigators get a picture of patient's training, pay attention to shortness of breath, potential for adaptation.~In the control arm of the study, this force adjustment would not take place, i.e. it is an endurance training of the diaphragm (10% of PI Max over the whole 6 weeks) with, however, also the control dates of the training twice a week. At least in the 6 weeks of the study (see above).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory Muscle Training (IMT)
Description: The training itself includes 2 x 30 breathing cycles per day. The whole training should take place daily, 7 days a week. The initial training intensity in the treatment arm (resistance of the respiratory muscle training) is set to 50% of the maximum respiratory muscle strength (measured using PImax). Once a week the present investigators get a picture of patient's training, pay attention to shortness of breath, potential for adaptation.~In the control arm of the study, this force adjustment would not take place, i.e. it is an endurance training of the diaphragm (10% of PI Max over the whole 6 weeks) with, however, also the control dates of the training twice a week. At least in the 6 weeks of the study (see above).
Study: NCT05788185

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVM-V001 30 µg
Description: For BNT162b2 subjects

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVM-V002 30 µg
Description: For BNT162b2 subjects

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration
Description: For BNT162b2 subjects

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVM-V001 30 µg
Description: For BBIBP-CorV or CoronaVac subjects

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVM-V002 30 µg
Description: For BBIBP-CorV or CoronaVac subjects

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration
Description: For BBIBP-CorV or CoronaVac subjects
Study: NCT04929184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech and non-speech tasks
Description: Participants will complete speech tasks such as listening to and/or producing speech and non-speech sounds.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech and non-speech tasks
Description: Participants will complete speech tasks such as listening to and/or producing speech and non-speech sounds.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Speech and non-speech tasks
Description: Participants will complete speech tasks such as listening to and/or producing speech and non-speech sounds.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Speech and non-speech tasks
Description: Participants will complete speech tasks such as listening to and/or producing speech and non-speech sounds.
Study: NCT04823949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Description: See arm description
Study: NCT04813185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bridging the Gap
Description: Bridging the Gap Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.~Firearm Counseling Program The firearm counseling program was developed to be administered in the hospital alongside the 6-step intervention program, as well as in the patient's home after hospital discharge. The firearm safety counseling program includes 3 components aimed at understanding patient risk, reducing firearm-related violence risk-factors, and helping patients increase firearm safety practices.
Study: NCT05099640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC923
Description: PTC923 powder for oral use will be suspended in water or apple juice prior to administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC923
Description: PTC923 powder for oral use will be suspended in water or apple juice prior to administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to PTC923
Study: NCT06374017

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline, Lidocaine, dexmetomidine
Description: The study drug of each group will be sprayed into oropharynx, the vocal cords and tracheal tree 3 minutes after induction of anesthesia and 5 minutes before intubation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline, Lidocaine, dexmetomidine
Description: The study drug of each group will be sprayed into oropharynx, the vocal cords and tracheal tree 3 minutes after induction of anesthesia and 5 minutes before intubation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline, Lidocaine, dexmetomidine
Description: The study drug of each group will be sprayed into oropharynx, the vocal cords and tracheal tree 3 minutes after induction of anesthesia and 5 minutes before intubation.
Study: NCT05315921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrhAAT 1 mg/kg IV
Description: Drug: OsrhAAT 1 mg/kg IV A single dose of OsrhAAT 1 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrhAAT 3 mg/kg IV
Description: Drug: OsrhAAT 3 mg/kg IV A single dose of OsrhAAT 3 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrhAAT 10 mg/kg IV
Description: Drug: : OsrhAAT 10 mg/kg IV A single dose of OsrhAAT 10 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrhAAT 20 mg/kg IV
Description: Drug: OsrhAAT 20 mg/kg IV A single dose of OsrhAAT 20 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrhAAT 40 mg/kg IV
Description: Drug: OsrhAAT 40 mg/kg IV A single dose of OsrhAAT 40 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrhAAT 60 mg/kg IV
Description: Drug: OsrhAAT 60 mg/kg IV A single dose of OsrhAAT 60 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)
Study: NCT06148558

Intervention type: OTHER
Group type: OTHER
Intervention: Sunscreen Moisturizer
Description: A provided anti-aging sunscreen moisturizer SPF 50 was used once a day.

Intervention type: OTHER
Group type: OTHER
Intervention: Gentle Cleansing Lotion
Description: A provided Gentle Cleansing Lotion (Revision Skincare) was used 2x daily (AM/PM).

Intervention type: OTHER
Group type: OTHER
Intervention: Facial Moisturizer
Description: A provided facial moisturizer (Goodier) was used 1x daily (PM).
Study: NCT05047276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AloCelyvir
Description: Delivery of Icovir-5 by mesenchymal carrier cells in uveal melanoma patients with hepatic metastases.
Study: NCT05835479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-Trimoxazole
Description: Oral co-trimoxazole or Intravenous (IV) co-trimoxazole for infusion. Anti fungal medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezafungin Acetate / Co Trimoxazole
Description: Rezafungin for infusion. Intravenous anti fungal therapy~Oral co-trimoxazole or Intravenous (IV) co-trimoxazole for infusion. Anti fungal medication
Study: NCT05894343

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV-GAD
Description: Bilateral infusion of AAV-GAD
Study: NCT05707923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linguistic simplification
Description: Children will participate in screen-based language processing and word learning tasks in which they hear utterances with different types and amounts of linguistic simplification (i.e., a within-group manipulation).
Study: NCT06471270

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: histologic evaluation
Description: histologic evaluation

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: histologic evaluation
Description: histologic evaluation

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: histologic evaluation
Description: histologic evaluation

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: histologic evaluation
Description: histologic evaluation

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: biochemical analysis
Description: IL-6, IL-8 and sCD44

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: biochemical analysis
Description: IL-6, IL-8 and sCD44

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: biochemical analysis
Description: IL-6, IL-8 and sCD44

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: biochemical analysis
Description: IL-6, IL-8 and sCD44

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: clinical examination
Description: clinical examination

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: clinical examination
Description: clinical examination

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: clinical examination
Description: clinical examination

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: clinical examination
Description: clinical examination
Study: NCT06460116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-Based Community Health Worker (SB-CHW) intervention
Description: The school-based community health worker will support students with chronic poor attendance and their parent/guardian for a minimum of two 30-minute encounters focused on addressing social determinants needs, understanding the range/student encounter varies greatly due to the intensity of the social need(s) (e.g., crisis/noncrisis) and the number of needs being jointly addressed. The SB-CHW will build relationships across encounters and apply trauma-informed best practices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC) Methods
Description: The network of school-based health centers without school-based community health workers will receive reminders of the the existing online social services directory.
Study: NCT05808244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tgCBFI
Description: Six weekly sessions CBT-based family intervention programme

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual psychiatric care
Description: Integrated community psychiatric care with medical follow-up

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual psychiatric care
Description: Integrated community psychiatric care with medical follow-up
Study: NCT04863703

Intervention type: DRUG
Intervention: Bulevirtide
Description: Patients with liver cirrhosis and HBV/HDV coinfection receive Bulevirtide as an antiviral therapy irrespective of the study, this study is observational.
Study: NCT04931992

Intervention type: OTHER
Intervention: No intervention
Description: Retrospective analysis

Intervention type: OTHER
Intervention: No intervention
Description: Retrospective analysis

Intervention type: OTHER
Intervention: No intervention
Description: Retrospective analysis
Study: NCT05697510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Administration of siltuximab at day 8 of induction following a classical induction; 3 dose levels : 7, 9 and 11mg/kg
Study: NCT04931004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mouthwash Product
Description: Commercially over-the-counter Colgate mouthwashes will be administered according to standard package instructions. Viral load will be measured prior to and after mouth rinse using serial face mask and saliva samples.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mouthwash Product
Description: Commercially over-the-counter Colgate mouthwashes will be administered according to standard package instructions. Viral load will be measured prior to and after mouth rinse using serial face mask and saliva samples.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mouthwash Product
Description: Commercially over-the-counter Colgate mouthwashes will be administered according to standard package instructions. Viral load will be measured prior to and after mouth rinse using serial face mask and saliva samples.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water rinse
Description: 30-second water rinse will occur in the control group. Viral load will be measured prior to and after water rinse using serial face mask and saliva samples.
Study: NCT05271513

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non invasive repetitive magnetic stimulation (real Transcranial + real trans-spinal )
Description: repetitive transcranial magnetic stimulation and trans-spinal magnetic stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non invasive repetitive magnetic stimulation (real Transcranial + sham trans-spinal )sham trans-spinal magnetic stimulation
Description: sham trans-spinal magnetic stimulation
Study: NCT04750551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreEStim
Description: BreEStim will applied for 10 to 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EStim
Description: EStim will applied for 10 to 20 minutes.
Study: NCT05018234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noval Oral Appliance
Description: A scan of the mouth will be performed to make the oral device. The device will be 3D printed with Asiga UV Max printer using FDA 510(k) cleared VeriSplint OS Resin.Subjects will be will be asked to wear the oral device at night for 3 nights and fill out a survey reviewing their experience wearing the device.
Study: NCT05722665

Intervention type: OTHER
Intervention: Categorization of chest xrays images
Description: Use of Convolutional Neural Network Model to categorize chest xrays images in each group.

Intervention type: OTHER
Intervention: Categorization of chest xrays images
Description: Use of Convolutional Neural Network Model to categorize chest xrays images in each group.

Intervention type: OTHER
Intervention: Categorization of chest xrays images
Description: Use of Convolutional Neural Network Model to categorize chest xrays images in each group.